GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Net Income From Continuing Operations

Acticor Biotech (XPAR:ALACT) Net Income From Continuing Operations : €-18.65 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Acticor Biotech's net income from continuing operations for the six months ended in Jun. 2023 was €-10.08 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was €-18.65 Mil.

Acticor Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Acticor Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Net Income From Continuing Operations Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial -5.99 -5.05 -7.65 -12.61 -15.88

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only -5.91 -6.70 -7.31 -8.57 -10.08

Acticor Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-18.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acticor Biotech (XPAR:ALACT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:ALCLS XPAR:ABNX XPAR:ALGEN XPAR:GNRO XPAR:ALVIO XPAR:PHXM XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:ALVAL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
7V7:Germany
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Website
https://www.acticor-biotech.com
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines